Company intelligence / Profile preview

Icure Pharmaceutical Inc.

South Korea

Ownership: Private
Employees: ~218
Development stage: Commercial

Overview

Icure developed the world’s first donepezil transdermal patch for Alzheimer’s dementia, which received regulatory approval in Korea after successful Phase III trials. The company is expanding its pipeline with additional transdermal patches and oral IMDs targeting CNS diseases, metabolic disorders, and gastrointestinal conditions. Its manufacturing facilities are cGMP certified.[1][6][8]

Therapeutic areas: GastroenterologyEndocrinologyNeurology
Modalities: Transdermal drug delivery systems (TDDS) / patches[1][6][10]Oral formulations (incrementally modified drugs)[8]
Industry: Biotech

Drug pipeline

3 assets

donepezil

Commercial

Indications: Alzheimer's disease

2 more assets in the full pipeline.

Request access →

Partnerships

Hanall Biopharma—technology transfer agreement on GERD IMDs.[8]Collaborations with various pharma companies to expand DDS applications.[5]

Beyond the preview

Go deeper on Icure Pharmaceutical Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Icure Pharmaceutical Inc..

Explore the full profile